M&A Deal Summary

Vertex Pharmaceuticals Acquires Catalyst Biosciences - Protease Medicines

On May 23, 2022, Vertex Pharmaceuticals acquired life science company Catalyst Biosciences - Protease Medicines for 60M USD

Acquisition Highlights
  • This is Vertex Pharmaceuticals’ 6th transaction in the Life Science sector.
  • This is Vertex Pharmaceuticals’ 7th largest (disclosed) transaction.
  • This is Vertex Pharmaceuticals’ 5th transaction in the United States.
  • This is Vertex Pharmaceuticals’ 2nd transaction in California.

M&A Deal Summary
Date 2022-05-23
Target Catalyst Biosciences - Protease Medicines
Sector Life Science
Buyer(s) Vertex Pharmaceuticals
Deal Type Divestiture
Deal Value 60M USD

Target

Catalyst Biosciences - Protease Medicines

San Francisco, California, United States
Catalyst Biosciences' Protease Medicines that regulate complement, including CB 2782-PEG. Catalyst Biosciences' Protease Medicines is based in San Francisco, California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vertex Pharmaceuticals

Boston, Massachusetts, United States
Category Company
Founded 1989
Sector Life Science
Employees5,400
Revenue 9.9B USD (2023)
DESCRIPTION

Vertex Pharmaceuticals is a biotechnology company that aims to discover, develop, and commercialize innovative new medicines so people with serious diseases can lead better lives. Vertex Pharmaceuticals was founded in 1989 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 6 of 8
Sector (Life Science) 6 of 8
Type (Divestiture) 2 of 2
State (California) 2 of 3
Country (United States) 5 of 7
Year (2022) 1 of 2
Size (of disclosed) 7 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-03 Semma Therapeutics

Cambridge, Massachusetts, United States

Semma Therapeutics is a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes. Semma Therapeutics was formed in 2015 and is based in Cambridge, Massachusetts.

Buy $950M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-11 ViaCyte

San Diego, California, United States

ViaCyte is a private cellular therapy company with a clinical-stage stem cell platform that delivers therapeutic proteins to restore health in people. The company has significant clinical experience in patients with T1D; this includes a first-in-class gene-edited, immune-evasive investigational islet cell replacement therapy for diabetes that could potentially eliminate the need for exogenous insulin without requiring immunosuppression. It has received support for its research from JDRF and the California Institute of Regenerative Medicine and has established collaborative partnerships with leading companies, including CRISPR Therapeutics, to advance its therapies for T1D. ViaCyte is based in San Diego, California.

Buy -
Mergr

Product

Company

Legal